Shattuck Labs, Inc., a biotechnology company, develops antibodies for the treatment of inflammatory and immune-mediated diseases. The company's lead product candidate is SL-325, a monoclonal antibody which activates immune responses through binding a single receptor, DR3; and SL-425. It also develops multiple preclinical DR3-based bispecific antibodies for the treatment of inflammatory bowel disease. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas.

Shattuck Labs Inc.

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Tandem Diabetes Care (TNDM – Research Report), Lemai...

Analysts Offer Insights on Healthcare Companies: Tandem Diabetes Care (TNDM), Lemaitre Vascular (LMAT) and Shattuck Labs (STTK)

Shattuck Labs, Inc. ( ($STTK) ) has released its Q3 earnings. Here is a breakdown of the information Shattuck Labs, Inc. presented to its investors...

Market Cap	$127.19M	P/E Ratio	N/A
52W High	$2.71	52W Low	$0.69
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	-11.7%	52W Position	66.5%
Overall Score	55	Value Score	60
Quality Score	--	Technical Score	50

EPS Current Est	$-0.7	EPS Next Est	$-0.42
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	STTK	$2.03	+5.18%	93.71K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	STTK	$2.03	+5.2%	93.71K
3
4
5
6

STTK

STTK

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Shattuck Labs Inc. Data in Excel

Get Shattuck Labs Inc. Data in Excel